Starfish Info
Home
The Starfish Story
Donations
Sponsors
Board of Advisors
HonoUr U
News
Association By-Laws
In the Open
Contacts
   
 
   
Starfish Projects
Autographed Items
Slow Onset Disaster
Dance4HIV
Initiatives
Events with Rutger
   
  
   
HIV/AIDS Info
What is HIV/AIDS
4 Kidz Only
News
Day out of Days
   
 
   
LINKS
Our Friends
Rutger's Website
   
   

Drug-Resistant HIV Worries Government
The Herald Zimbabwe
By Ropafadzo Ndangariro
August 9, 2017


Thirty five percent of people on antiretroviral drugs in Zimbabwe are on second line treatment either because they are not recovering on first line treatment or they are reacting to treatment, Health and Child Care Minister Dr David Parirenyatwa has said. In an interview on the sidelines of the World Breastfeeding Week commemorations held in Harare recently, Dr Parirenyatwa said second line drugs were an alternative but were expensive.

"We are now aware that 35 percent of our people are on second line drugs which means there is some resistance. It is, however, not always resistance that they are put on second line, sometimes you just react to the first line drugs," said Dr Parirenyatwa.

He said should people already on second line drugs fail the treatment again, Government would be left with no choice but to switch them to third line treatment.

Third line treatment is even more expensive.

Dr Parirenyatwa said Government was concerned more financial resources would be required to fight drug-resistant HIV.

"We need to continue educating our people that if you are on ARVs, take them religiously otherwise you foster resistance," said Dr Parirenyatwa.

According to the National Aids Council, it costs about $200 to test for drug-resistant HIV in public institutions and about $600 in private institutions.

Local figures on how much is required to treat drug-resistant HIV could not be easily obtained.

In its latest report, WHO said the world requires an extra $6,5 billion in 2030.

Back to International News List


 

©Rutger Hauer Starfish Association 1999-2017
Terms of use - Disclaimer